Skip to content

Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image

Artificial Intelligence to Optimize Early-stage Hepatocellular CarcinomaTreatment Based on Multi-modal Image

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05627297
Acronym
AI-HCC
Enrollment
200
Registered
2022-11-25
Start date
2022-12-01
Completion date
2025-11-01
Last updated
2022-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

This study intends to establish two prognostic models based on contrast-enhanced ultrasound (CEUS) and dynamic enhanced magnetic resonance (DE-MRI) multimodal images: prognostic model of liver cancer patients after hepatectomy and prognostic model of liver cancer patients after radiofrequency ablation. Combined with artificial intelligence imaging omics, traditional imaging omics and clinical information, to predict and compare the prognosis of two different treatment methods for early liver cancer, so as to realize the individual selection of treatment methods for early liver cancer patients

Interventions

OTHERCEUS and CEMRI

contrast-enhanced ultrasound and contrast-enhanced MRI examination

Sponsors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Primary single hepatocellular carcinoma confirmed by histology or cytology, with a maximum diameter ≤5.0 cm; * Good liver function, Child-Pugh grade A; * No serious dysfunction of heart, lung, kidney and other important organs ④ Liver resection or radiofrequency ablation was performed in our hospital, and the study protocol and follow-up procedure were followed.

Exclusion criteria

* Patients who cannot perform DCE-MRI examination due to metal implants in the body ② Patients who had received other treatment before DCE-MRI or CEUS; * Invisible lesions, diffuse lesions or poor DCE-MRI/CEUS image quality under CEUS; ④ Drug abuse, clinical or psychological or social factors that make informed consent or study implementation affected.

Design outcomes

Primary

MeasureTime frame
Good/Poor overall survival2022/12/01-2025/12/01

Countries

China

Contacts

Primary ContactWentao Kong
breezewen@163.com13815897824
Backup ContactHan Liu
liuhanDEonly@163.com13058328870

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026